NCT07014449View on ClinicalTrials.gov

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 3, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
AML (Acute Myelogenous LeukemiaRelapsed Acute Myelogenous LeukemiaRefractory Acute Myeloid LeukemiaHematologic MalignancyC-MycAdult Acute Myeloid Leukemia
Interventions
DRUG

WBC100 QD

WBC100 will be administered orally as capsules once daily in 28-day cycles. The dose-escalation phase follows an accelerated titration combined with the traditional '3+3' design.

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Hangzhou Weben Pharma Co., Ltd

INDUSTRY